Effect of Multisite High-definition Transcranial Direct Current Stimulation Targeting Sensorimotor Network
Launched by CHINESE UNIVERSITY OF HONG KONG · Oct 17, 2024
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to help stroke recovery using a technique called multisite high-definition transcranial direct current stimulation (HD-tDCS). This method aims to improve movement in patients who have had a stroke by targeting specific areas in the brain that control motor skills. Traditional stimulation often focuses on just one part of the brain, but this new method looks at multiple areas at once, potentially leading to better results in improving hand movements.
To be eligible for this trial, participants should have had their first stroke at least 12 months ago and have mild to moderate difficulty with using their arm, as measured by a specific assessment tool. Participants should also be able to follow instructions and perform simple hand movements. However, those with a history of seizures or certain physical conditions that affect their arms or shoulders may not qualify. Participants can expect to receive the stimulation in a comfortable setting while being monitored, and they will help researchers understand if this new method can lead to better recovery outcomes for stroke patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. first-ever stroke, the duration after stroke exceeds 12 months;
- • 2. mild to moderate upper extremity motor function deficit, determined by the Fugl-meyer assessment of upper extremity (FMAUE) scores between 15 and 53;
- • 3. could voluntarily perform grasping hand movement.
- • 4. sufficient cognitive function to follow the assessment and experiment instructions.
- Exclusion Criteria:
- • 1. history of epilepsy, or any other contradictions of brain stimulation and MRI scanning;
- • 2. severe joint contracture of elbow or shoulder, or pain induced by any other neurological, neuromuscular, and orthopedic diseases.
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Raymond Kai-yu Tong, PhD
Principal Investigator
Department of Biomedical Engineering, CUHK
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported